Can-Fite BioPharma and National Institutes of Health (NIH) Signed a Continuation of M-CRADA to Further Investigate CF101 for the Treatment of Uveitis

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced today the successful completion of a preclinical trial with CF101 in the treatment of uveitis. This preliminary trial was conducted in a leading laboratory at the National Eye Institute (NEI), which is part of the US National Institute of Health (NIH). The trial, which examined the effect of CF101 in a preclinical animal model, demonstrated that the drug was able to significantly reduce ocular disease symptoms via a definitive immunological mechanism of action.

Back to news